(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 October 2011 (06.10.2011)

PCT

(10) International Publication Number
WO 2011/121558 A1

(51) International Patent Classification:
A61K 31/00 (2006.01) *A61K 31/4433* (2006.01)
A61K 31/427 (2006.01) *A61K 31/4545* (2006.01)
A61K 31/4402 (2006.01) *A61K 31/472* (2006.01)
A61K 31/46 (2006.01) *A61K 31/4725* (2006.01)
A61K 45/06 (2006.01) *A61K 31/496* (2006.01)
A61P 31/18 (2006.01) *A61K 31/499* (2006.01)
A61K 31/351 (2006.01) *A61K 31/506* (2006.01)
A61K 31/4178 (2006.01)

(21) International Application Number:
PCT/IB2011/051370

(22) International Filing Date:
30 March 2011 (30.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/320,428 2 April 2010 (02.04.2010) US

(71) Applicant *(for all designated States except US)*: **PHIV-CO-1 LLC** [US/US]; Corporation Trust Center 1209 Orange Street, Wilmington, Delaware 19801 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **TRESSLER, Randall, Lee** [US/US]; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US). **VALDEZ, Hernan** [PE/US]; Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(74) Agent: **BENSON, Gregg C.**; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: COMBINATION THERAPY COMPRISING A CCR5 ANTAGONIST, A HIV-1 PROTEASE INHIBITOR AND A PHARMACOKINETIC ENHANCER

(57) Abstract: The present invention discloses a novel combination therapy for HIV-1 treatment relying on a combination of at least one CCR5 antagonist, at least one HIV-1 protease inhibitor and at least one pharmacokinetic enhancer of said at least one CCR5 antagonist and/or at least one HIV-1 protease inhibitor. The combination is intended for use in oral treatment of a disorder selected from the group consisting of HIV-1 infection, retroviral infections genetically related to HIV and AIDS, in a treatment-naive patient infected with CCR5 tropic HIV-1 virus.

WO 2011/121558 A1